Fixed-Dose Ibuprofen–Acetaminophen Tablets for Stable Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing over-the-counter analgesics like ibuprofen and acetaminophen often fail to provide complete relief from pain or fever at maximum recommended doses, leading to adverse events, and their combination formulations face challenges in large-scale manufacturing due to chemical degradation and physical form conversion during processing.
Innovation Solution
A novel composition of ibuprofen and acetaminophen tablets, formulated with a specific ratio and excipients such as pregelatinized starch and Hypromellose, avoids chemical degradation and physical form conversion, ensuring effective pain relief and fever reduction with lower doses, while being suitable for large-scale manufacturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If maximum recommended doses of single analgesics are used, then pain relief efficacy is improved, but risk of adverse events increases
Solution Approach 1:
The patent combines two analgesics with different mechanisms of action (ibuprofen as NSAID and acetaminophen as non-NSAID) into a single fixed-dose combination product. This multimodal approach provides synergistic pain relief and fever reduction, allowing effective treatment at lower individual doses of each component, thereby reducing the risk of dose-dependent adverse events while maintaining or improving therapeutic efficacy
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing both ibuprofen and acetaminophen in specific ratios (e.g., 200mg/500mg or 400mg/1000mg). This composite structure leverages the complementary pharmacological properties of both drugs, achieving broader and more reliable pain relief and antipyretic effects while distributing the dosing burden across two agents with different safety profiles
2Reliability
If ibuprofen and acetaminophen are combined in fixed-dose formulation, then therapeutic efficacy is improved, but manufacturing stability deteriorates due to chemical degradation and physical form conversion
Solution Approach 1:
The patent segments the combination formulation into separate granules or particles containing ibuprofen and acetaminophen, rather than using a homogeneous mixture. This physical separation prevents direct chemical interactions between the two active ingredients during processing and storage, eliminating degradation issues while maintaining the fixed-dose combination's therapeutic benefits
Solution Approach 2:
The invention introduces inert excipients and coating materials as intermediaries between ibuprofen and acetaminophen. These materials act as barriers that prevent direct contact and potential chemical reactions between the two actives during manufacturing processes such as granulation, compression, and storage, thereby ensuring formulation stability without compromising efficacy
3Reliability
If higher doses of ibuprofen and acetaminophen are administered, then pain relief is improved, but safety profile deteriorates
Solution Approach 1:
The patent optimizes the dosage parameters of the fixed-dose combination to achieve effective pain relief at lower individual component doses. By carefully selecting the ratio and amount of each analgesic (e.g., 200mg ibuprofen with 500mg acetaminophen), the formulation achieves synergistic effects that provide adequate analgesia while staying below the threshold for significant adverse events associated with higher doses of either drug alone
Data Source
AI summary
The present invention provides novel compositions, methods of treatment and methods of manufacture of large scale, commercially viable ibuprofen and acetaminophen tablets. The unique characteristics and synergistic effects resulting from the disclosed compositions, methods of treatment and methods of manufacture demonstrate a product with optimal analgesia, anti-pyresis, safety profiles and large-scale manufacturability. The inventions described herein surprisingly show the unique composition and method of manufacturing for a large-scale commercial batch of a novel ibuprofen and acetaminophen tablet.